Treatment of uncomplicated gonorrhoea with rosoxacin (acrosoxacin).
An open study was designed primarily to evaluate the efficacy of rosoxacin in the treatment of gonorrhoea caused by penicillinase producing Neisseria gonorrhoeae (PPNG) and non-PPNG strains. A total of 199 patients (99 men and 100 women) satisfactorily completed follow up examinations, 50 men and 50 women having received rosoxacin 300 mg orally and the remainder having received kanamycin 2 g intramuscularly. Rosoxacin achieved an overall cure rate of 94% (96.7% for PPNG and 90% for non-PPNG strains). In patients treated with kanamycin the overall cure rate was 89.9% (92.7% for PPNG and 83.3% for non-PPNG strains). A correlation between treatment failures and minimum inhibitory concentrations (MICs) of rosoxacin was noted in non-PPNG strains but not in PPNG strains. Side effects which were mild and self limiting were noted in 15 of 100 patients treated with rosoxacin. The high failure rates associated with non-PPNG strains requiring MICs of 0.125 mg/l and the observation of a substantial rise in the MICs for isolates after treatment is of concern. Otherwise, rosoxacin in a single dose of 300 mg appears to be safe and effective for the treatment of uncomplicated gonorrhoea.
D042462:4-Quinolones; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000201:enzymology; D010405:Penicillinase / Q000096:biosynthesis; D011804:Quinolines / Q000627:therapeutic use*; D015363:Quinolones; D011477:Sex Work
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D011804:Quinolines; D015363:Quinolones; C021083:rosoxacin; D007612:Kanamycin; D010405:Penicillinase